Apalutamide 60mg Tab

DRUG3 trials

Sponsors

Universität Münster, University of British Columbia, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Conditions

Biochemical RecurrenceHigh RiskProstate CancerProstatic Neoplasms

Phase 2

Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy

Active, not recruitingNCT04295447

Universität MünsterProstatic Neoplasms

Start: 2020-12-10End: 2028-11-30Target: 190Updated: 2024-06-20

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

RecruitingNCT04812366

University of British ColumbiaProstate Cancer

Start: 2021-09-21End: 2027-06-01Target: 315Updated: 2026-08-14

Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)

Not yet recruitingNCT05778097

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolBiochemical Recurrence, High Risk, Prostate Cancer

Start: 2023-04-01End: 2026-12-31Target: 103Updated: 2023-03-21

Related Papers

3D Structural Revelations of Neoadjuvant Hormonal Therapy Treatment in High Risk Localized Prostate Cancer by Light-Sheet Imaging.

Journal of Clinical Oncology2026-05-28

Safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer (SEGNO): study protocol for an open-label prospective phase II umbrella clinical trial.

2025-03-101 citations

Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study.

2025-03-074 citations

Genomic alterations and their pathologic responses in high-risk localized prostate cancer (HRLPC) in subprotocol 1 of the Genomic Umbrella Neoadjuvant study (GUNS).

Journal of Clinical Oncology2025-02-101 citations